Matrix-Bio Signs Metabolomics Biomarker Licensing Agreement with Quest Diagnostics for Development of Breast Cancer Recurrence Test
Posted April 11, 2013 by Matrix-Bio • No Comments
FORT WAYNE, IND., April 11, 2013 – Matrix-Bio, Inc., a diagnostics company that uses metabolite profiling to detect cancer and other diseases, has signed an exclusive global licensing and marketing agreement for metabolomic biomarkers with Quest Diagnostics (NYSE: DGX), the world’s leading provider of diagnostic information services.
No comments yet.
Sorry, the comment form is closed at this time.